title: Levetiracetam reduces myoclonus in corticobasal degeneration: report of two cases.
abstract: Levetiracetam (LEV) has been shown to suppress myoclonus of various origins. Corticobasal degeneration (CBD), a progressive neurodegenerative disorder with Parkinsonian syndrome, is frequently accompanied by myoclonus. We investigated the effect of LEV on myoclonus in two CBD patients. LEV remarkably decreased the myoclonic activity in both patients already at 1,500 mg/day dose. This is the first report on LEV alleviating myoclonus in CBD. Our data indicate that it might be worthwhile to assess this effect in an appropriately designed study.
authors.affiliation: Department of Neurology, Semmelweis University, 1083, Budapest, Balassa u. 6, Hungary. tibor@neur.sote.hu
authors.forename: Tibor
authors.initials: T
authors.lastname: Kovács
authors.forename: Marianna
authors.initials: M
authors.lastname: Farsang
authors.forename: Edina
authors.initials: E
authors.lastname: Vitaszil
authors.forename: Péter
authors.initials: P
authors.lastname: Barsi
authors.forename: Tamás
authors.initials: T
authors.lastname: Györke
authors.forename: Imre
authors.initials: I
authors.lastname: Szirmai
authors.forename: Anita
authors.initials: A
authors.lastname: Kamondi
mesh_terms: D000927:Anticonvulsants / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D000077287:Levetiracetam; D008297:Male; D008875:Middle Aged; D009207:Myoclonus / Q000188:drug therapy* / Q000209:etiology; D019636:Neurodegenerative Diseases / Q000150:complications / Q000188:drug therapy*; D010889:Piracetam / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000927:Anticonvulsants; D000077287:Levetiracetam; D010889:Piracetam